Hemoglobin News and Research

RSS

Cardiometabolic risk high for schizophrenia patients

The risk for abdominal obesity may be increased as much as fourfold for patients with multi-episode schizophrenia compared with the rest of the population, reveal findings from a meta-analysis.

17 Oct 2013

Sleep deprivation may have vascular consequences

Sleep deprivation enlarges the blood vessels and reduces vascular compliance, according to research published in Sleep.

14 Oct 2013

Running a marathon can damage heart muscle for unfit runners

Investigators who studied a group of recreational marathon runners have established that strenuous exercise such as running a marathon can damage the heart muscle. Although they found the effect is temporary and reversible, they warn that these effects are more widespread in less fit distance runners and that recreational distance runners should prepare properly before marathons.

10 Oct 2013

High blood glucose levels associated with higher risk of wound-related complications

A new study released today shows that among patients undergoing surgery for chronic wounds related to diabetes, the risk of wound-related complications is affected by how well the patient's blood sugar levels are controlled before surgery. These findings appear in the October issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

2 Oct 2013

DiaRem score predicts diabetes remission after gastric bypass

A new scoring system offers a “scientifically valid” way of predicting the 5-year likelihood for diabetes remission in patients undergoing gastric bypass surgery, say the researchers who developed the score.

20 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

Iron levels hint at resistance to harmful effects of smoking

Researchers from Japan say that serum iron levels could be a biomarker that indicates which smokers are resistant to the effects of cigarette smoke on lung function.

19 Sep 2013

Oil spill exposure appears to play role in development of hematologic and hepatic toxicity

A new study reports that workers exposed to crude oil and dispersants used during the Gulf oil spill cleanup display significantly altered blood profiles, liver enzymes, and somatic symptoms compared to an unexposed control group.

17 Sep 2013

Arginine therapy may be safe treatment for patients with sickle cell disease

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

17 Sep 2013

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

The benefits of hydroxyurea treatment in people with sickle cell disease are well known -- fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.

12 Sep 2013

Study: Nearly 12% of Chinese adults have diabetes and about 50% at risk of developing the disease

A study based on a nationally representative sample of adults in China in 2010 indicates that nearly 12 percent of Chinese adults had diabetes and the prevalence of prediabetes was about 50 percent, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.

2 Sep 2013

Implementation of better blood-management plan changes culture at UAB

Blood is in big demand at the University of Alabama at Birmingham Hospital, once the fourth largest user of blood among U.S. hospitals served by the American Red Cross. And although blood transfusions can be life-saving during cancer care, trauma, surgery, transplants and difficult pregnancies, supply doesn't always rise to meet demand.

27 Aug 2013

Researchers outline recommendations to lower costs and lead to better care for patients

Medical organizations are participating in a campaign to help clinicians and patients avoid wasteful and sometimes harmful medical interventions. Recently, experts in pediatric and adult health from diverse geographic locations of the United States and from a mix of academic and non- academic settings shared their experiences, consulted their colleagues, and analyzed numerous studies in the medical literature to determine the top recommendations for improving healthcare value.

20 Aug 2013

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls.

20 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Health benefits of sufficient sleep: an interview with Dr Monique Verschuren, National Institute for Public Health and the Environment, the Netherlands

We used 6 hours or less per 24 hours as the definition of insufficient sleep, with 7 hours or more as sufficient sleep. In general, this is considered the amount of sleep that is sufficient for adults, although there can be differences between persons with respect to the amount of sleep needed.

6 Aug 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis.